argenex (ARGX) Projected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX) is expected to release its Q2 2026 resultson Thursday, July 23rd. Analysts expect the company to post earnings of $5.86 per share and revenue of $1.45 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. On average, analysts expect argenex to post $26 EPS for the current fiscal year and $34 EPS for the next fiscal year.

argenex Price Performance

Shares of argenex stock opened at $874.74 on Wednesday. The stock’s 50-day moving average is $862.87 and its 200 day moving average is $813.72. argenex has a one year low of $563.08 and a one year high of $953.58. The firm has a market cap of $54.72 billion, a price-to-earnings ratio of 38.95, a PEG ratio of 1.05 and a beta of 0.45.

Analyst Ratings Changes

Several equities analysts have issued reports on ARGX shares. HC Wainwright reissued a “buy” rating and issued a $940.00 price target on shares of argenex in a research note on Thursday, June 25th. Wells Fargo & Company lifted their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research note on Monday, June 1st. Oppenheimer dropped their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Bank of America increased their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, Citigroup raised their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $1,042.67.

Institutional Trading of argenex

A number of hedge funds and other institutional investors have recently bought and sold shares of ARGX. CI Investments Inc. raised its stake in argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after buying an additional 12 shares during the last quarter. Raiffeisen Bank International AG boosted its stake in shares of argenex by 12.6% in the 4th quarter. Raiffeisen Bank International AG now owns 134 shares of the company’s stock worth $112,000 after buying an additional 15 shares during the last quarter. Laird Norton Wetherby Wealth Management LLC boosted its stake in shares of argenex by 2.7% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,253 shares of the company’s stock worth $924,000 after buying an additional 33 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of argenex by 6.9% in the 2nd quarter. Thrivent Financial for Lutherans now owns 527 shares of the company’s stock worth $295,000 after buying an additional 34 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC grew its holdings in shares of argenex by 10.8% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 391 shares of the company’s stock worth $328,000 after acquiring an additional 38 shares during the period. Institutional investors own 60.32% of the company’s stock.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.